N2OFF shares surge 12.50% premarket after rebranding to Nexentis and MitoCareX's positive in vitro data in oncology and inflammatory diseases.

N2OFF Inc. (NITO) surged 12.5% in premarket trading following the announcement of its corporate rebranding to Nexentis Technologies, reflecting a strategic pivot to an AI and data-driven computational biotech platform focused on mitochondrial biology. The rebranding, effective February 26, 2026, underscores the company’s integration of MitoCareX Bio Ltd., a wholly-owned subsidiary with proprietary MITOLINE™ technology targeting mitochondrial SLC25 carriers in oncology and inflammatory metabolic diseases. Recent validation of MITOLINE’s in vitro anti-inflammatory efficacy and plans to advance preclinical candidates reinforced the rebranding’s emphasis on first-in-class drug discovery. The shift from cleantech to biotech, coupled with the subsidiary’s projected $120 billion market opportunity for inflammatory metabolic therapies, signaled to investors a repositioning toward high-growth therapeutic areas, driving the premarket rally.